Cover Image


Ebola Virus Vaccine Market & Pipeline Insight

出版商 KuicK Research 商品編碼 316840
出版日期 內容資訊 英文 80 Pages
商品交期: 最快1-2個工作天內
Back to Top
伊波拉病毒疫苗的市場及開發平台分析 Ebola Virus Vaccine Market & Pipeline Insight
出版日期: 2014年10月20日 內容資訊: 英文 80 Pages



第1章 伊波拉病毒感染疾病市場概要

  • 症狀、診斷
  • 伊波拉病毒感染疾病的原因
  • 罹患率
  • 開發情形
  • 未來方案

第2章 伊波拉疫苗的臨床試驗概要

第3章 伊波拉疫苗臨床試驗分析:各相、企業、國家

  • 研究
  • 前臨床
  • 臨床
  • 第一階段

第4章 延期、中止的伊波拉疫苗臨床試驗分析:各相、企業、國家

  • 沒有發展的報告
  • 中止
  • 延期

第5章 競爭環境

  • Bavarian Nordic
  • Crucell
  • Fab Entech
  • Inovio Pharmaceuticals
  • Microbiotix
  • 田邊三菱製藥
  • Profectus Biosciences
  • SIGA Technologies
  • Tekmira Pharmaceuticals
  • Vaxart



Ebola virus infection, which was previously called Ebola hemorrhagic fever, was discovered in 1976. The infection caused due to Ebola virus originates from four different strains of Ebola virus. These viruses generally are known to affect non-human primates, and are transmitted from wild animals to the humans and among the latter, it is known to spread through human-to-human transmission. The natural hosts of Ebola virus are Fruit bats, which belong to the Pteropodidae family.

Ebola virus is mostly found among primates in the African region, (mainly in the remote villages of Central and West Africa, near tropical rainforests) and in the Philippines. Other than Africa, this infection has been observed in regions like Republic of Congo, Gabon, Sudan, Ivory Coast and Uganda.

In terms of treatment, till date, there is not standard treatment method for Ebola hemorrhagic fever. Only supportive therapy is available. Also, there is no licensed vaccine for Ebola virus infection which is of clinical use. The researchers have been trying to better understand this virus and target its ecological reservoirs in order to get a deeper understanding of the cause and nature of the outbreaks of this disease. There are currently many experiments in the laboratories which are focusing on developing an appropriate vaccine for the prevention of this disease, but no success has been met till now.

The pharma companies have a significant opportunity in the field of Ebola virus infections in terms of developing drugs, vaccines and introducing measures to control and prevent the spread of the disease. After the success of the clinical candidates, and the market approval of these drugs or vaccines, it is most likely that there could a significant demand for these products from the physicians and patients. Additionally, due to the nature of the disease, these products would be priced at a premium, which would eventually yield high revenues for the companies which would earn a significant return on investment.

“Ebola Virus Vaccine Market & Pipeline Insight” Report Highlight:

  • Ebola Virus Infection Market Overview
  • Ebola Vaccine Clinical Trial Insight by Phase, Company & Country
  • Ebola Vaccine in Clinical Trials: 26 Vaccine
  • Majority Ebola Vaccine in Preclinical Phase: 15 Vaccines
  • Ebola Vaccines by Mechanism of Action, Drug Class, Route of administration, Patent Analysis & Licensing Status

Table of Contents

1. Ebola Virus Infection Market Overview

  • 1.1. Symptoms & Diagnostics
  • 1.2. Causes of Ebola Virus Infection
  • 1.3. Incidence
  • 1.4. Ongoing developments
  • 1.5. Future Scenario

2. Ebola Vaccine Clinical Trial Overview

3. Ebola Vaccine Clinical Trial Insight by Phase, Company & Country

  • 3.1. Research
  • 3.2. Preclinical
  • 3.3. Clinical
  • 3.4. Phase-I

4. Suspended & Discontinued Ebola Vaccine Clinical Trial Insight by Phase, Company & Country

  • 4.1. No Development Reported
  • 4.2. Discontinued
  • 4.3. Suspended

5. Competitive Landscape

  • 5.1. Bavarian Nordic
  • 5.2. Crucell
  • 5.3. Fab Entech
  • 5.4. Inovio Pharmaceuticals
  • 5.5. Microbiotix
  • 5.6. Mitsubishi Tanabe Pharma
  • 5.7. Profectus Biosciences
  • 5.8. SIGA Technologies
  • 5.9. Tekmira Pharmaceuticals
  • 5.10. Vaxart

List of Figures:

  • Figure 1-1: Ebola Incidence & Deaths, October'2014
  • Figure 2-1: Ebola Vaccine Clinical Trial by Phase (%), 2014
  • Figure 2-2: Ebola Vaccine Clinical Trial by Phase (Number), 2014
  • Figure 2-3: Suspended & Discontinued Ebola Vaccine in Clinical Trial by Phase (%), 2014
  • Figure 2-4: Suspended & Discontinued Ebola Vaccine in Clinical Trial by Phase (Number), 2014

List of Tables:

  • Table 1-1: Ebola Incidence Since 1976
Back to Top